Emmy D.G. Fleuren

This study identifies METTL1 gene dosage and catalytic activity as therapeutic targets in pediatric cancers, showing that inhibiting METTL1 synergizes with BCL-xL inhibitors.

The paper identifies FGFR aberrations as actionable targets in pediatric and AYA sarcomas using multi-platform profiling and shows FGFR inhibitors can inhibit tumor growth in PDX models.

This paper develops patient-derived tumour models using engineered ECM hydrogels to enable precision medicine for paediatric cancers by retaining tumour genotype and phenotype.